MALDI-TOF: pre-2016
The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.
The company plans to launch a PCR-based test for measuring three genes in the plasma of lung cancer patients and is also at work on an NGS-based panel.
Study Links Epigenetic Markers to Intensive Weight-Loss Program Success
NEW YORK (GenomeWeb News) – A handful of epigenetic biomarkers are associated with good response to an intensive weight-loss program, researchers in Spain reported in The FASEB Journal this week.
Biodesix Inks Deal w/Bruker for Mass Spec Support; Closes on $8.8M Series D Financing
NEW YORK (GenomeWeb News) – Biodesix said it has entered a collaborative agreement with Bruker Daltonics to support its VeriStrat diagnostic test as well as future tests based on MALDI-TOF mass spectrometry.